The market for biotech IPOs is experiencing its best run in nine years, with 16 companies...


The market for biotech IPOs is experiencing its best run in nine years, with 16 companies raising $1.1B in H1. An increase in FDA drug approvals, a strong performance by some biotech firms that are already listed, and the JOBS Act, which allows companies to privately "test the waters" before publicly launching an IPO process, are some of the factors behind the trend. Companies to benefit include heart-drug company Esperion Therapeutics (ESPR), and Prosensa Holding (RNA), a developer of treatments for rare diseases.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs